DXCM · 10-Q · 2026Q3 · Full report
Capital Return Program
DEXCOM INC · 2026-10-29 · Importance 58 · Surprise 82 · In source text
Net cash used in financing activities was $1,023.8 million for the nine months ended September 30, 2026, an $859.6 million increase from the prior-year period. The increase included $816.4 million more cash used to repurchase common stock and $39.2 million more in taxes paid for net share settlement of equity awards. Dexcom said its 2026 Share Repurchase Program was completed in the third quarter of 2026. The company expects to allocate at least 50% of cash generated from operations, net of planned capital expenditures, to share repurchases over its long-range plan.
Key facts
- Nine-month 2026 financing cash flows included an $816.4 million increase in cash used to repurchase common stock and a $39.2 million increase in taxes paid for net share settlement of equity awards. source
- Dexcom intends to allocate at least 50% of cash generated from operations, net of planned capital expenditures, to share repurchases over its long-range plan. source
- Dexcom expects to continue using cash to repurchase common stock, including under share repurchase programs, or for other strategic initiatives that strengthen long-term growth. source
- Dexcom completed its 2026 Share Repurchase Program in the third quarter of 2026. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | contingent | — | Dexcom intends to allocate at least 50% of cash generated from operations, net of planned capital expenditures, to share repurchases over… |